Direct Transformation of Lung Microenvironment by Interferon-α Treatment Counteracts Growth of Lung Metastasis of Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhuang, Peng Yuan ^a,b   Shen, Jun ^a   Zhu, Xiao Dong ^b   Zhang, Ju Bo ^b   Tang, Zhao You ^b   Qin, Lun Xiu ^b   Sun, Hui Chuan ^b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG METASTASIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLULAR MICROENVIRONMENT; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; LUNG NEOPLASMS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875074784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058913     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, et al. (2004) A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196.
3. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
4. Katyal S, Oliver JH, 3rd, Peterson MS, Ferris JV, Carr BS, et al (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216: 698-703.
5. Tomimaru Y, Sasaki Y, Yamada T, Eguchi H, Takami K, et al. (2006) The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg 192: 46-51.
6. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507.
7. Arii S, Monden K, Niwano M, Furutani M, Mori A, et al. (1998) Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg 5: 86-92.
8. Poon RT, Fan ST, O'Suilleabhain CB, Wong J, (2002) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195: 311-318.
9. Jonasch E, Haluska FG, (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55.
10. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, et al. (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95: 437-448.
11. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, et al. (2000) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32: 43-48.
12. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, et al. (2003) Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7: 587-594.
13. Wada H, Nagano H, Yamamoto H, Arai I, Ota H, et al. (2007) Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 18: 801-809.
14. Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, et al. (2010) Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1891-1900.
15. Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, et al. (2008) Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 112: 1765-1771.
16. Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, et al. (2008) Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 75: 8-16.
17. Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, et al. (2007) Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110: 2493-2501.
18. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, et al. (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228-232.
19. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, et al. (2001) Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134: 963-967.
20. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, et al. (2003) Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138: 299-306.
21. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, et al. (2004) Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100: 376-382.
22. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, et al. (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245: 831-842.
23. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, et al. (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44: 1543-1554.
24. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, et al. (2006) Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132: 458-465.
25. Chambers AF, Groom AC, MacDonald IC, (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
26. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, et al. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300.
27. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, et al. (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68: 6251-6259.
28. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
29. Yang BW, Liang Y, Xia JL, Sun HC, Wang L, et al. (2008) Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur J Gastroenterol Hepatol 20: 1077-1084.
30. Li Y, Tang Y, Ye L, Liu B, Liu K, et al. (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129: 43-51.
31. Li Y, Tian B, Yang J, Zhao L, Wu X, et al. (2004) Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 130: 460-468.
32. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, et al. (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716.
33. Nozawa H, Chiu C, Hanahan D, (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 12493-12498.
34. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
35. Coussens LM, Tinkle CL, Hanahan D, Werb Z, (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
36. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
37. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, et al. (2005) Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65: 7320-7327.
38. van Deventer HW, O'Connor W Jr, Brickey WJ, Aris RM, Ting JP, et al. (2005) C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 65: 3374-3379.
39. Brown DM, Ruoslahti E, (2004) Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5: 365-374.